309 related articles for article (PubMed ID: 38504070)
41. Role of anti-angiogenic factors in the pathogenesis of breast cancer: A review of therapeutic potential.
Ruan L; Zhang S; Chen X; Liang W; Xie Q
Pathol Res Pract; 2022 Aug; 236():153956. PubMed ID: 35700578
[TBL] [Abstract][Full Text] [Related]
42. Anti-angiogenic therapy against gastrointestinal tract cancers.
Iwasaki J; Nihira S
Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
[TBL] [Abstract][Full Text] [Related]
43. [Benefits and Prospects of VEGF-targeted Anti-angiogenic Therapy and Immunotherapy for High-grade Glioma].
Ishikawa E; Miyazaki T
No Shinkei Geka; 2021 May; 49(3):597-607. PubMed ID: 34092565
[TBL] [Abstract][Full Text] [Related]
44. Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma.
Jain S; Chalif EJ; Aghi MK
Front Oncol; 2021; 11():812916. PubMed ID: 35096619
[TBL] [Abstract][Full Text] [Related]
45. Cancer immunotherapy of targeting angiogenesis.
Hou J; Tian L; Wei Y
Cell Mol Immunol; 2004 Jun; 1(3):161-6. PubMed ID: 16219162
[TBL] [Abstract][Full Text] [Related]
46. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
47. Immunotherapy of tumor by targeting angiogenesis.
Hou J; Tian L; Wei Y
Sci China C Life Sci; 2004 Dec; 47(6):545-52. PubMed ID: 15620111
[TBL] [Abstract][Full Text] [Related]
48. Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review).
Katoh M
Int J Mol Med; 2013 Oct; 32(4):763-7. PubMed ID: 23863927
[TBL] [Abstract][Full Text] [Related]
49. In pursuit of new anti-angiogenic therapies for cancer treatment.
Cai J; Han S; Qing R; Liao D; Law B; Boulton ME
Front Biosci (Landmark Ed); 2011 Jan; 16(3):803-14. PubMed ID: 21196204
[TBL] [Abstract][Full Text] [Related]
50. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Caponigro F; Basile M; de Rosa V; Normanno N
Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of tumor angiogenesis by angiostatin: from recombinant protein to gene therapy.
Dell'Eva R; Pfeffer U; Indraccolo S; Albini A; Noonan D
Endothelium; 2002; 9(1):3-10. PubMed ID: 12901356
[TBL] [Abstract][Full Text] [Related]
52. Angiopoietin inhibitors: A review on targeting tumor angiogenesis.
Parmar D; Apte M
Eur J Pharmacol; 2021 May; 899():174021. PubMed ID: 33741382
[TBL] [Abstract][Full Text] [Related]
53. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
Lopes-Coelho F; Martins F; Pereira SA; Serpa J
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438
[TBL] [Abstract][Full Text] [Related]
54. Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies.
Procaccio L; Damuzzo V; Di Sarra F; Russi A; Todino F; Dadduzio V; Bergamo F; Prete AA; Lonardi S; Prenen H; Palozzo AC; Loupakis F
Drug Saf; 2019 Feb; 42(2):159-179. PubMed ID: 30649744
[TBL] [Abstract][Full Text] [Related]
55. VEGF-Independent Angiogenic Factors: Beyond VEGF/VEGFR2 Signaling.
Eguchi R; Kawabe JI; Wakabayashi I
J Vasc Res; 2022; 59(2):78-89. PubMed ID: 35152220
[TBL] [Abstract][Full Text] [Related]
56. Tumor angiogenesis: Current challenges and therapeutic opportunities.
Al-Ostoot FH; Salah S; Khamees HA; Khanum SA
Cancer Treat Res Commun; 2021; 28():100422. PubMed ID: 34147821
[TBL] [Abstract][Full Text] [Related]
57. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
[TBL] [Abstract][Full Text] [Related]
58. Limitations of the dorsal skinfold window chamber model in evaluating anti-angiogenic therapy during early phase of angiogenesis.
Biel NM; Lee JA; Sorg BS; Siemann DW
Vasc Cell; 2014; 6():17. PubMed ID: 25101168
[TBL] [Abstract][Full Text] [Related]
59. The protein biosynthesis inhibitor vioprolide A evokes anti-angiogenic and pro-survival actions by targeting NOP14 and decreasing VEGF receptor 2- and TAZ-signaling.
Burgers LD; Li Y; Michalakis S; Ciurus S; Zahler S; Müller R; Fürst R
Biomed Pharmacother; 2022 Aug; 152():113174. PubMed ID: 35665668
[TBL] [Abstract][Full Text] [Related]
60. [Research Progress of Small Molecule Anti-angiogenic Drugs
in Non-small Cell Lung Cancer].
Dou Y; Jiang D
Zhongguo Fei Ai Za Zhi; 2021 Jan; 24(1):56-62. PubMed ID: 33478192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
